Search results: (10000)
News To what extent can the actual level of ALP, ALT, or bilirubin differ from the measured value?
A physician who bases clinical decisions on laboratory-determined values of biological parameters or their changes should always consider the possible measurement deviation, which for alkaline phosphatase (ALP), alanine aminotransferase (ALT), or bilirubin can reach several percent in both positive and negative directions.
News Options for Preventing Enteral Nutrition Intolerance in Mechanically Ventilated Patients in the ICU
Standards of care for critically ill patients recommend enteral nutrition for those on mechanical ventilation. A recently published study addressed the question of how to identify patients at risk of enteral nutrition intolerance (ENI) and how to subsequently prevent this intolerance, which may be associated with worse clinical outcomes.
News European Registry of Patients with Alpha-1 Antitrypsin Deficiency EARCO Enrolls Patients
Insufficient identification of patients with alpha-1 antitrypsin deficiency (AATD) and a lack of knowledge about this disease have led to the launch of the European Registry EARCO, which is currently enrolling patients. The aim is to better describe the pathophysiology of the disease and the prognosis of these patients, and to create a validated prognostic tool to aid clinical decision-making.
News Can alpha-1-antitrypsin deficiency affect severity and higher mortality in COVID-19 patients?
Alpha-1-antitrypsin (AAT) deficiency is commonly found in the European population. The most cases are recorded in countries with the highest COVID-19 mortality rates. Are there direct correlations?
News Effectiveness of the Venetoclax/Rituximab Combination in the Treatment of CLL – 5-Year Follow-Up Data
At the virtual 62nd Annual Meeting of the American Society of Hematology (ASH), updated results of a clinical evaluation of the treatment of patients with refractory/relapsed chronic lymphocytic leukemia (R/R CLL) using venetoclax in combination with rituximab were presented.
News Does Beta-Blocker Therapy Reduce the Cardiovascular Benefit of Aerobic Exercise in Patients with Arterial Hypertension?
Regular aerobic exercise is generally recommended for patients suffering from arterial hypertension to reduce blood pressure values, improve physical fitness, and other parameters. The intensity of exercise is most often derived from the target heart rate, which is pharmacologically influenced in patients on beta-blockers. The question, therefore, is whether aerobic exercise brings the same cardiovascular benefit to this group of patients as it does to those not taking beta-blockers.
News Experiences with Long-term Treatment of Psoriasis with Interleukin 17A Inhibitor
The current publication of the long-term extension of the UNCOVER-3 study, which focused on the treatment of psoriasis with ixekizumab, describes the efficacy and safety of 4 years of use of this drug.
News Obeticholic Acid in the Treatment of Patients with Primary Biliary Cholangitis with Inadequate Response to Ursodeoxycholic Acid in Real Practice
An interim analysis of the OCARELIFE observational study presented at the European Association for the Study of the Liver (EASL) congress in August 2020 attempted to evaluate whether the safety and efficacy of obeticholic acid treatment in patients with primary biliary cholangitis (PBC) under real-life conditions after 12 months correspond to the results of clinical trials.
News Dysregulation of microRNA Expression After Treatment with Anti-EGFR Antibodies
A team of researchers from Plzeň decided to verify whether treatment with anti-EGFR antibodies changes the expression of selected microRNAs in patients with metastatic colorectal carcinoma (mCRC). They have just published their findings in the autumn issue of the journal Cancer Genomics Proteomics.
News Panitumumab in 1st Line in Older Patients – Results of the PANDA Study
The phase II PANDA study evaluated the regimens FOLFOX + panitumumab versus 5-FU + panitumumab in the 1st line treatment of patients with wt-RAS/BRAF metastatic colorectal cancer (mCRC).
News COVID-19 and Immune Thrombocytopenic Purpura − Spanish Experience Suggests Surprising Connections
In a retrospective study examining the impact of COVID-19 on immune thrombocytopenic purpura, Spanish authors surprisingly observed a paradoxical effect.
News Current Data on the Safety Profile of Baricitinib in the Treatment of Rheumatoid Arthritis
Baricitinib was approved for the treatment of rheumatoid arthritis (RA) in 2017, making it essential and relevant to monitor its safety profile in clinical practice. The analysis of data collected over 8.4 years presented below provides current insights.
News Efficacy of Baricitinib in Long-term Therapy of Rheumatoid Arthritis
Baricitinib selectively and reversibly inhibits Janus kinases JAK1 and JAK2 and is used in the treatment of adults with active rheumatoid arthritis (RA). Its safety during long-term administration has already been demonstrated by previous analyses, with treatment durations of up to 7 years. Equally important is the long-term efficacy of this drug, which was the focus of work presented in June of this year at the annual European rheumatology congress EULAR 2020.
News Targeted Treatment and Quality of Life in Patients with Follicular Lymphoma
The GALLIUM clinical trial evaluated chemotherapy in combination with targeted treatment using rituximab or obinutuzumab in previously untreated patients with advanced follicular lymphoma (FL). A secondary aim of the study was to assess the health-related quality of life. The results of the analysis were recently published in the journal Annals of Hematology.
News Sport Therapy as Part of Hemophilia Management
A study by authors from the University of Wuppertal in Germany specifically examined the impact of a half-year programmed sport therapy on the subjective physical performance and quality of life of individuals with hemophilia.